Society Spotlight: The Association for Molecular Pathology Joins FASEB as its Newest Member Society Created by on 7/11/2013 12:00:00 AM
FASEB welcomed the Association for Molecular Pathology (AMP) on July 1 as its twenty-seventh member society. As an international medical and professional association, AMP represents over 2,000 physicians, doctoral scientists, laboratory personnel, and medical technologists who participate in basic and translational research aimed at broadening the understanding of gene/protein structure and function, disease processes, and molecular diagnostics.
As a part of its mission, AMP strives to keep its members abreast of the latest advances in, and applications of nucleic acid-based diagnostics through its annual meetings, website, and The Journal of Molecular Diagnostics, the official publication of AMP. In addition, the Association offers an online members-only forum that fosters discussion, world-wide collaborations, and real-time information exchange.
Although the majority of its members are located within the US, AMP understands the global benefit of connecting health care professionals and laboratory scientists from around the world. To further advance molecular pathology and expand membership outside of North America, AMP created an International Affairs Working Group. As a result of its efforts, molecular pathology-related organizations in Hong Kong, Korea, and India have recently become official AMP affiliates. Today, AMP members can be found on all continents except for Antarctica.
Through its advocacy program, AMP continuously aims to inform and influence public policy related to professional and economic issues affecting molecular pathology by representing its membership to the federal agencies and Congress. Its policy committees act as primary liaisons between the Association and other organizations, legislators, and the public to develop AMP positions on emerging issues relevant to molecular pathology and genomics. Most recently, AMP submitted comments to several federal agencies regarding gap fill payment amounts, genetic testing, drug labeling, and health information technology.
In June, AMP celebrated an important victory when, in a landmark decision made by the US Supreme Court (Association for Molecular Pathology et al v. Myriad Genetics, Inc. et al, No. 12-398, U.S. (2013)), human DNA was declared not patent eligible. “There is no question that this is a critical and right decision for the future of medicine and science,” said AMP President Jennifer L. Hunt, MD, MEd, in a recent AMP press release. “Biomedical researchers, clinicians, and most importantly patients, will see great benefit from this development.”
AMP will hold its 2013 Annual Meeting on November 14-16 in Phoenix, AZ, which will include nearly 400 posters and 150 exhibitors, as well as a one-day course for pathologists, laboratory directors and technologists to gain experience with molecular pathology testing. For more information about the upcoming annual meeting or to learn more about the AMP, visit its website at http://www.amp.org.